Robert Glassman, a healthcare pro who advised Pfizer on its purchase of Wyeth last year, has returned to Bank of America Merrill Lynch as a managing director on its healthcare corporate and investment banking team.
Glassman was for the last year a private-equity partner at Orbimed Advisors, the world’s largest healthcare-dedicated investment firm. Bank of America Merrill Lynch announced his return in a press release on Wednesday.
Glassman will be based in New York. He reports to Joseph Kohls, head of Americas healthcare corporate and investment banking.
Glassman, who studied medicine at Harvard’s medical school, was a dealmaker with Merrill Lynch for eight years before he decamped for Orbimed. He is a board certified hematologist-oncologist and is a clinical professor at Weill-Cornell University Medical College and New York Presbyterian Hospital.
Before he worked with Merrill Lynch, Glassman was with McKinsey & Co. for four years consulting for healthcare clients in the U.S. and Europe.
Other deals Glassman was involved with as a healthcare banker at Merrill before he left for Orbimed include the $1 billion sale of Cougar to J&J, the $1.8 billion sales of Lifecell to KCI.
He also advised Eli Lilly on its minority investment in United Therapeutics and has been involved with taking several companies public, among them Insulet, Aspreva, and Cadence.
